Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Abrogating mitochondrial ROS in neurons or astrocytes reveals cell-specific impact on mouse behaviour

  • Vicente-Gutiérrez, Carlos
  • Bonora, Nicoló
  • Jimenez-Blasco, Daniel
  • López-Fabuel, Irene
  • Bates, Georgina
  • Murphy, Michael P.
  • Almeida, Angeles
Cells naturally produce mitochondrial reactive oxygen species (mROS), but the in vivo pathophysiological significance has long remained controversial. Within the brain, astrocyte-derived mROS physiologically regulate behaviour and are produced at one order of magnitude faster than in neurons. However, whether neuronal mROS abundance differentially impacts on behaviour is unknown. To address this, we engineered genetically modified mice to down modulate mROS levels in neurons in vivo. Whilst no alterations in motor coordination were observed by down modulating mROS in neurons under healthy conditions, it prevented the motor discoordination caused by the pro-oxidant neurotoxin, 3-nitropropionic acid (3-NP). In contrast, abrogation of mROS in astrocytes showed no beneficial effect against the 3-NP insult. These data indicate that the impact of modifying mROS production on mouse behaviour critically depends on the specific cell-type where they are generated., J.P.B. is funded by the Agencia Estatal de Investigación (SAF2016-78114-R, PID2019-105699RB-I00/AEI/10.13039/501100011033 and RED2018-102576-T), Plan Nacional sobre Drogas (2020I028), ISCIII (CB16/10/00282), Junta de Castilla y Le ́on (Escalera de Excelencia CLU-2017-03), Ayudas Equipos Investigación Biomedicina 2017 Fundaci ́on BBVA and Fundaci ́on Ram ́on Areces. A.A. is funded by the ISCIII (PI18/00265, RD16/0019/0018), AEI (SAF2017-90794-REDT) and European Union’s Horizon 2020 Research and Innovation Program (Grant Agreement 686009). J.P.B. and A.A. are funded by the grant CSI151P20 from the Junta de Castilla y Leon.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Opa1 relies on cristae preservation and ATP synthase to curtail reactive oxygen species accumulation in mitochondria

  • Quintana-Cabrera, Ruben
  • Manjarrés-Raza, Israel
  • Vicente-Gutiérrez, Carlos
  • Corrado, Mauro
  • Bolaños, Juan P.
  • Scorrano, Luca
Reactive oxygen species (ROS) are a common product of active mitochondrial respiration carried in mitochondrial cristae, but whether cristae shape influences ROS levels is unclear. Here we report that the mitochondrial fusion and cristae shape protein Opa1 requires mitochondrial ATP synthase oligomers to reduce ROS accumulation. In cells fueled with galactose to force ATP production by mitochondria, cristae are enlarged, ATP synthase oligomers destabilized, and ROS accumulate. Opa1 prevents both cristae remodeling and ROS generation, without impinging on levels of mitochondrial antioxidant defense enzymes that are unaffected by Opa1 overexpression. Genetic and pharmacologic experiments indicate that Opa1 requires ATP synthase oligomerization and activity to reduce ROS levels upon a blockage of the electron transport chain. Our results indicate that the converging effect of Opa1 and mitochondrial ATP synthase on mitochondrial ultrastructure regulate ROS abundance to sustain cell viability., R.Q.-C was supported by an AIRC and a Fondazione Veronesi fellowship and by a H2020 Marie Sklodowska-Curie IEF GA793987. J.P.B. is funded by Agencia Estatal de Investigación (PID2019-105699RB-I00/AEI/10.13039/501100011033 and RED2018‐102576‐T), Instituto de Salud Carlos III (CB16/10/00282), Escalera de Excelencia CLU-2017-03, Ayudas Equipos Investigación Biomedicina 2017 Fundación BBVA and Fundación Ramón Areces. This work was supported by AIRC IG19991, Italian Ministry of Education, University and Research PRIN 2017BF3PXZ, Fondation Leducq TNE15004, Muscular Dystrophy Association (MDA USA) RG 603731 and Cariparo Foundation SIGMI (to L.S.).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Astrocyte-neuron metabolic cooperation shapes brain activity

  • Bonvento, Gilles
  • Bolaños, Juan P.
The brain has almost no energy reserve, but its activity coordinates organismal function, a burden that requires precise coupling between neurotransmission and energy metabolism. Deciphering how the brain accomplishes this complex task is crucial to understand central facets of human physiology and disease mechanisms. Each type of neural cell displays a peculiar metabolic signature, forcing the intercellular exchange of metabolites that serve as both energy precursors and paracrine signals. The paradigm of this biological feature is the astrocyte-neuron couple, in which the glycolytic metabolism of astrocytes contrasts with the mitochondrial oxidative activity of neurons. Astrocytes generate abundant mitochondrial reactive oxygen species and shuttle to neurons glycolytically derived metabolites, such as L-lactate and L-serine, which sustain energy needs, conserve redox status, and modulate neurotransmitter-receptor activity. Conversely, early disruption of this metabolic cooperation may contribute to the initiation or progression of several neurological diseases, thus requiring innovative therapies to preserve brain energetics., G.B. received grants from the Centre National de la Recherche Scientifique (CNRS), the Commissariat à l’Energie Atomique et aux Energies Alternatives (CEA), Agence Nationale de la Recherche (ANR 2011 MALZ-0003 MetALZ; ANR-18-C816-0008-03 ADORASTrAU), Association France Alzheimer, Fondation de France (Prix Spécial 2012), Fondation Alzheimer, and Infrastructure de Recherche Translationnelle pour les Biothérapies en Neurosciences (NeurATRIS ANR-11-INBS-0011). J.P.B. is funded by the Agencia Estatal de Investigación (PID2019-105699RB-I00 / AEI / 10.13039/501100011033 and RED2018-102576-T), Instituto de Salud Carlos III (CB16/10/00282), Junta de Castilla y León (CSI151P20 and Escalera de Excelencia CLU-2017-03), Ayudas Equipos Investigación Biomedicina 2017 Fundación BBVA, and Fundación Ramón Areces.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Consensus document on frailty: conceptualization, detection, multidisciplinary management and future roadmap

  • Álvarez-Bustos, Alejandro
  • Andrés-Lacueva, Cristina
  • Ara, Ignacio
  • Arévalo, María Ángeles
  • Bolaños, Juan P.
  • Coto, Ana
  • Enríquez, José Antonio
  • Escames, Germaine
  • García-García, Francisco José
  • Gómez-Cabrera, Mari Carmen
  • Grau, Oriol
  • Izquierdo, Mikel
  • Martínez Velilla, Nicolás
  • Matheu, Ander
  • Menéndez Colino, Rocío
  • Muñoz Torres, Manuel
  • Nogués, Xavier
  • Oliva, Juan
  • Orts-Cortés, María Isabel
  • Párraga Martínez, Ignacio
  • Priego, Feliciano
  • Rabassa, Montserrat
  • Rol, María Ángeles
  • Serra-Rexach, José Antonio
  • Tarazona-Santabalbina, Francisco José
  • Rodríguez-Mañas, Leocadio
  • Abizanda, Pedro
The lack of a universally accepted definition, a gold-standard assessment tool, and sufficient evidence-based interventions has hindered the integration of frailty into routine clinical practice, particularly outside geriatric medicine. For clinicians, health professionals, policymakers, and aging researchers, a unified framework based on robust evidence has become essential., The present study received funding from the projects CB16/10/00408, CB16/10/00269, CB16/10/00477, CB16/10/00383, CB16/10/00282, CB16/10/00289, CB16/10/00238, CB16/10/00456, CB16/10/00435, CB16/10/00417, CB16/10/00315, CB16/10/00496, CB16/10/00468, CB16/10/00475, CB16/10/00245, CB23/10/00037, CB16/10/00501, CB16/10/00464, CB16/10/00239, CB16/10/00314, Instituto de Salud Carlos III, Madrid, Spain., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Shaping current European mitochondrial haplogroup frequency in response to infection: the case of SARS-CoV-2 severity

  • Cabrera-Alarcon, José Luis
  • Cruz, Raquel
  • Rosa-Moreno, Marina
  • Latorre-Pellicer, Ana
  • de Almeida, Silvia Diz
  • Abellan, Javier
  • Acosta-Isaac, René
  • Aguado, Jose María
  • Aguilar, Carlos
  • Aguilera-Albesa, Sergio
The frequency of mitochondrial DNA haplogroups (mtDNA-HG) in humans is known to be shaped by migration and repopulation. Mounting evidence indicates that mtDNA-HG are not phenotypically neutral, and selection may contribute to its distribution. Haplogroup H, the most abundant in Europe, improved survival in sepsis. Here we developed a random forest trained model for mitochondrial haplogroup calling using data procured from GWAS arrays. Our results reveal that in the context of the SARS-CoV-2 pandemic, HV branch were found to represent protective factors against the development of critical SARS-CoV-2 in an analysis of 14,349 patients. These results highlight the role of mtDNA in the response to infectious diseases and support the proposal that its expansion and population proportion has been influenced by selection through successive pandemics.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

Consensus document on frailty: conceptualization, detection, multidisciplinary management and future roadmap

  • Álvarez Bustos, Alejandro
  • Andrés-Lacueva, Cristina
  • Ara, Ignacio
  • Arévalo, María Ángeles
  • Bolaños, Juan P.
  • Coto-Montes, Ana
  • Enríquez, José Antonio
  • Escames, Germaine
  • García García, Francisco José
  • Gómez Cabrera, Mari Carmen
  • Grau-Rivera, Oriol
  • Izquierdo Redín, Mikel
  • Martínez Velilla, Nicolás
  • Matheu, Ander
  • Menéndez Colino, Rocío
  • Muñoz Torres, Manuel
  • Nogués, Xavier
  • Oliva Moreno, Juan
  • Orts-Cortés, María Isabel
  • Párraga Martínez, Ignacio
  • Priego, Feliciano
  • Rabassa-Bonet, Montserrat
  • Rol, María Ángeles
  • Serra-Rexach, José Antonio
  • Tarazona-Santabalbina, Francisco José
  • Rodríguez Mañas, Leocadio
  • Abizanda, Pedro
  • CIBERFES Working Group
Background: The lack of a universally accepted definition, a gold-standard assessment tool, and sufficient evidence-based interventions has hindered the integration of frailty into routine clinical practice, particularly outside geriatric medicine. For clinicians, health professionals, policymakers, and aging researchers, a unified framework based on robust evidence has become essential. Objectives: To provide a consensus on relevant aspects of frailty, including definition, attributes, misunderstandings, pathophysiology, phenotypes, assessment, biomarkers, management, stigmas and future challenges, useful for epidemiological, clinical and research application across Europe. Design: Consensus document. Setting: 25 research centers on frailty and healthy aging. Measurements: Relevant aspects on frailty. Results: In this document we present a consensus regarding what frailty is, what frailty is not, what is aging, which are the most common misunderstandings related to frailty, which is the pathophysiology and which are the biomarkers of frailty, how should frailty be assessed and who should assess frailty, how should frailty be managed, the presence or absence of frailty subphenotypes or subtypes, how is the stigma of been considered frail, which are the gender considerations, and which are the current challenges and future directions. We support that frailty is the expression of an age-associated clinical phenotypic syndrome driven by the biology of aging, life-course environmental exposures, and disease burden. Its physiological basis lies in a heterogeneous decline of functional reserve across organ systems, accompanied by impaired homeostasis and reduced capacity to respond to stressors, ultimately predisposing to adverse health outcomes, mainly disability. Conclusions: We present a consensus document on frailty, useful for epidemiological, clinical and research application across Europe., The present study received funding from the projects CB16/10/00408, CB16/10/00269, CB16/10/00477, CB16/10/00383, CB16/10/00282, CB16/10/00289, CB16/10/00238, CB16/10/00456, CB16/10/00435, CB16/10/00417, CB16/10/00315, CB16/10/00496, CB16/10/00468, CB16/10/00475, CB16/10/00245, CB23/10/00037, CB16/10/00501, CB16/10/00464, CB16/10/00239, CB16/10/00314, Instituto de Salud Carlos III, Madrid, Spain.